References
Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic signaling during inflammation. N Engl J Med 367:2322–2333. doi:10.1056/NEJMra1205750
Sugiyama T (2014) Role of P2X7 receptors in the development of diabetic retinopathy. World J Diabetes 5:141–145. doi:10.4239/wjd.v5.i2.141
Costa G, Pereira T, Neto AM, Cristovao AJ, Ambrosio AF, Santos PF (2009) High glucose changes extracellular adenosine triphosphate levels in rat retinal cultures. J Neurosci Res 87:1375–1380. doi:10.1002/jnr.21956
Loukovaara S, Sahanne S, Jalkanen S, Yegutkin GG (2015) Increased intravitreal adenosine 5'-triphosphate, adenosine 5'-diphosphate and adenosine 5'-monophosphate levels in patients with proliferative diabetic retinopathy. Acta Ophthalmol 93:67–73. doi:10.1111/aos.12507
Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A (2000) Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care Suppl 2:B72–B78
Tuuminen R, Sahanne S, Loukovaara S (2014) Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment. Acta Ophthalmol 92:675–681. doi:10.1111/aos.12363
Lee SG, Kim JL, Lee HK, Ryu GW, Hur DY, Yun IH, Yang JW, Kim HW (2011) Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes. Graefes Arch Clin Exp Ophthalmol 249:389–397. doi:10.1007/s00417-010-1496-5
Jalkanen J, Yegutkin GG, Hollmen M, Aalto K, Kiviniemi T, Salomaa V, Jalkanen S, Hakovirta H (2015) Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis. Circ Res 116:1206–1215. doi:10.1161/CIRCRESAHA.116.305715
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was supported by grants from the Finnish Eye Foundation, the Eye and Tissue Bank Foundation, the Mary and Georg C. Ehrnrooth Foundation, the Nissi Foundation, the Waldemar von Frenckells Foundation, and HUCH Clinical research grants (TKK4150 and TYH1325). The sponsors had no role in the design or conduct of this research.
Conflict of Interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Tuuminen, R., Yegutkin, G.G., Jalkanen, S. et al. Simvastatin use associated with low intraocular ADP levels in patients with sight-threatening diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 254, 1643–1644 (2016). https://doi.org/10.1007/s00417-016-3349-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-016-3349-3